What You Should Know:
– Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer.
– This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate Real-World Evidence in Breast Cancer
As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network (LHN) to integrate, normalize, de-identify and manage data. The insights gleaned from this collaboration will help grow the breast cancer data cohort and provide Pfizer with in-depth, patient-level insights. Together, the two companies will continue to generate an unparalleled understanding of the oncology patient experience and develop a higher standard of care through real-world evidence.
– Syapse and Pfizer have co-authored two studies that utilize data from the LHN. The first study, titled “Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the Syapse Learning Health Network,” was presented at the 38th Annual Miami Breast Cancer Conference. The second study, titled “Germline BRCA1/2 Mutation Testing in Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer (ABC): A Real-World Study in the Syapse Learning Health Network (LHN),” was presented at the 2021 San Antonio Breast Cancer Symposium.